Gina M. Cavalier, a healthcare lawyer with extensive experience in regulatory counseling to medical device and pharmaceutical companies and healthcare providers and suppliers, has joined King & Spalding as a partner in its FDA and life sciences practice, in Washington, D.C., the firm announced today. Cavalier comes to King & Spalding from Reed Smith.
“We are pleased to welcome Gina to the firm. She has a well-earned reputation as an outstanding healthcare lawyer and makes a great addition to our team,” said Patrick Morrisey, co-chair of King & Spalding’s FDA and life sciences practice. “Gina’s considerable experience advising life sciences companies complements and expands our existing strengths as one of the leading FDA and healthcare regulatory practices.”
Cavalier has more than 15 years’ experience in healthcare law. She focuses on fraud and abuse counseling (anti-kickback, Stark/self-referral and false claim laws), HIPAA privacy and security, Medicare and Medicaid reimbursement, healthcare compliance programs and the administration of corporate integrity agreements. She is professionally certified in information privacy by the International Association of Privacy Professionals as a Certified Information Privacy Professional (CIPP). Cavalier earned a J.D., cum laude, from Georgetown University Law Center, and a B.A. with distinction, summa cum laude, from Boston University, where she was also Phi Beta Kappa.
Seth Lundy, deputy chair of the firm’s FDA and life sciences practice, said, “When coupled with King & Spalding’s substantial litigation capabilities, Gina’s regulatory and compliance experience and her client-focused approach further enhance our ability to handle the most challenging legal and enforcement matters for FDA-regulated companies.”
“I am delighted to join King & Spalding’s FDA and life sciences practice,” Cavalier said. “The firm’s reputation in the healthcare and life sciences industries — particularly its depth of experience on FDA issues, remarkably talented lawyers and focus on growth — offers extraordinary opportunities for someone with my experience.”
King & Spalding’s FDA and life sciences team comprises more than 40 lawyers and professional consultants who advise pharmaceutical, medical device and biotechnology companies on U.S. Food and Drug Administration and healthcare regulatory issues, compliance program development and implementation, internal investigations and enforcement issues. This group includes four lawyers who previously served in the FDA’s Office of Chief Counsel, one who served in the FDA’s Office of Regulatory Policy, one who served as acting general counsel of the U.S. Department of Health and Human Services, a former chief health counsel to the House Energy and Commerce Committee and four regulatory and quality system experts who served at the FDA. In addition, the firm’s extended healthcare team includes colleagues who have held senior positions within the U.S. Department of Justice and U.S. Department of Health and Human Services. King & Spalding represents more than 200 pharmaceutical, biotechnology and medical device manufacturers regulated by the FDA, including 15 of the top 20 pharmaceutical companies and 12 of the top 20 medical device companies.
